Eurasian Journal of Medical and Natural Sciences 4-jild 2-son (2024) · 13–14-betlar

A NEW ALTERNATIVE IN MIGRAINE TREATMENT: ELETRIPTAN HYDROBROMIDE BUCCAL ORGANOGELS

Naku, K., Mehmed, D. A., Güneş, M., Karavana, S.Y.

DOI: 10.5281/zenodo.10677928 · Manbada o'qish →

Annotatsiya

Migraine is a disorder characterized by severe, intermittent throbbing pain in the head, often accompanied by sensitivity to light and sound, as well as nausea and vomiting. Eletriptan hydrobromide (EHB) is a highly selective serotonin 5-HT1B/1D receptor agonist administered orally in the acute treatment of moderate or severe migraine attacks.  In migraine patients, pain-induced vomiting and nausea may complicate medication intake. Inhibition of critical gastrointestinal motility and delayed gastric emptying time during a migraine attack is also a major problem. Taking into consideration all these data, the importance of unconventional dosage forms in migraine treatment emerges. The fact is that buccal formulations are important in terms of rapid effect, easy use in patients with swallowing difficulties, and ease of use in patients with nausea/vomiting complaints, and in cases requiring drug intake without water.

Migraine, Buccal, Eletriptan hydrobromide, Organogel

Metadata manbasi: jurnal OAI-PMH arxivi · Sindex to'liq matnni saqlamaydi, manbaga havola beradi.